Bixlenvo approved as once-daily single-tablet regimen for virologically suppressed HIV adults
- Sponsor
- Gilead Sciences $GILD
- Drug
- Bixlenvo · bictegravir/lenacapavir
- Indication
- HIV-1 infection in virologically suppressed adults, including those on complex regimens
FDA approved Gilead's Bixlenvo (bictegravir 75 mg + lenacapavir 50 mg) as a once-daily single-tablet regimen for adults living with HIV who are virologically suppressed. Approval is based on the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials.
What this means
For adults living with HIV whose infection is already well controlled on treatment, Bixlenvo offers a new one-pill, once-a-day option. It combines two Gilead drugs: bictegravir, which blocks HIV from integrating into human DNA, and lenacapavir, a first-in-class drug that interferes with the virus's protein shell. In the Phase 3 ARTISTRY-1 and ARTISTRY-2 trials, patients who switched to Bixlenvo maintained virologic suppression at week 48 with no new safety concerns. Because lenacapavir has no cross-resistance with older HIV drugs, Bixlenvo may be especially useful for patients coming off complex multi-tablet regimens.